Lanean...
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance
Reactivated androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC). Novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanisms o...
Gorde:
| Argitaratua izan da: | Clin Pharmacol Ther |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4715745/ https://ncbi.nlm.nih.gov/pubmed/26331358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.256 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|